Integrating CSF and EV Proteomes Enhances Biomarker Discovery by Capturing Shared Variation Across Compartments
- 1Yale University
Abstract
Cerebrospinal fluid (CSF) contains brain derived proteins that can be leveraged as biomarkers for Alzheimer's disease (AD) and other neurodegenerative diseases. However, converting protein intensities to a disease signal remains a challenge because physiology driven changes to the localization of proteins across CSF subcompartments are obscured when CSF is analyzed alone. Where subcompartment data, such as that from extracellular vesicles (EVs), are also measured, separate but parallel analyses of EVs and CSF can obscure their shared disease signal. Here, we present an integrated matrix factorization approach that combines proteomic signals from matched CSF and phosphatidylserine exposed EVs and nanoparticles (EVps). In a ROS/MAP cohort of 48 participants, integrating CSF and EVps signals improved biological concordance across compartments and increased the number of candidate proteins distinguishing participants with AD from controls. Notably, the joint signal identified as many brain related biomarker candidates as studies using substantially larger cohorts. By demonstrating that integration of CSF and EVps proteomes maximizes information from limited samples, this framework offers a path toward more efficient biomarker discovery across two compartments increasingly leveraged in neurodegenerative disease research.
Related
- Integrating multi-omics with machine learning: from genomic variant functional annotation to pharmacogenomics and biomarker discovery
- ALSmiR: a curated evidence resource for ALS-associated microRNAs for biomarker discovery
- An alignment-last approach enables rapid transcriptomic biomarker discovery in large cohorts
- Integrating Multisource Target Evidence with Machine-Learning Potency Prediction for Alzheimer's Disease Drug Discovery
- The cGAS-STING pathway in acute myocardial infarction: Biomarker discovery and mechanistic insights
BibTeX
@misc{brown2026integrating,
title = {{Integrating CSF and EV Proteomes Enhances Biomarker Discovery by Capturing Shared Variation Across Compartments}},
author = {B. R. P. Brown and X. Li and M. R. Grasty and A. D. Miranker and G. Gursoy},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.30.754912},
url = {https://www.biorxiv.org/content/10.64898/2026.09.30.754912v1},
note = {CC BY-ND},
}
RIS
TY - UNPB
TI - Integrating CSF and EV Proteomes Enhances Biomarker Discovery by Capturing Shared Variation Across Compartments
AU - B. R. P. Brown
AU - X. Li
AU - M. R. Grasty
AU - A. D. Miranker
AU - G. Gursoy
PY - 2026
DA - 2026/09/30
PB - bioRxiv
DO - 10.64898/2026.09.30.754912
UR - https://www.biorxiv.org/content/10.64898/2026.09.30.754912v1
AB - Cerebrospinal fluid (CSF) contains brain derived proteins that can be leveraged as biomarkers for Alzheimer's disease (AD) and other neurodegenerative diseases. However, converting protein intensities to a disease signal remains a challenge because physiology driven changes to the localization of proteins across CSF subcompartments are obscured when CSF is analyzed alone. Where subcompartment data, such as that from extracellular vesicles (EVs), are also measured, separate but parallel analyses of EVs and CSF can obscure their shared disease signal. Here, we present an integrated matrix factorization approach that combines proteomic signals from matched CSF and phosphatidylserine exposed EVs and nanoparticles (EVps). In a ROS/MAP cohort of 48 participants, integrating CSF and EVps signals improved biological concordance across compartments and increased the number of candidate proteins distinguishing participants with AD from controls. Notably, the joint signal identified as many brain related biomarker candidates as studies using substantially larger cohorts. By demonstrating that integration of CSF and EVps proteomes maximizes information from limited samples, this framework offers a path toward more efficient biomarker discovery across two compartments increasingly leveraged in neurodegenerative disease research.
ER -